

The Application of Research Grade MetabolitePilot[™] Software for the Determination of Exenatide Catabolites using HRAM with SWATH Acquisition Jeff Plomley¹, Yi Zhang², Eva Duchoslav², Daniel Villeneuve¹, Kevork Mekhssian¹ and Anahita Keyhani¹

¹ Altasciences Clinical Research, Laval, QC; ² SCIEX, Concord, ON

Overview

Purpose

To implement research grade MetabolitePilot[™] software for the determination of *in vitro* catabolites of exenatide, a 4.2 kDa GLP-1 agonist.

Method


- Incubation of exenatide in rat whole blood at 37°C
- Extraction by protein precipitation in ethanol:acetonitrile (7:3)
- HRAM measurements of SWATH data acquired using a SCIEX TripleTOF5600+

Results

The MS/MS spectra of chromatographically unresolved exenatide(3-39) and (4-39) catabolites whose precursor masses were transmitted through the same SWATH window were successfully identified using the advanced spectral deconvolution algorithm in research grade MetabolitePilot[™].

Introduction

The stability of peptide/protein biotherapeutics directly impacts their pharmacokinetic profile, efficacy, and safety, making it essential to characterize potential metabolic soft spots. To facilitate an accurate mass workflow for the confirmation of peptide biotransformations and their profiling across a time course, a research grade version of MetabolitePilotTM software has been y_4 ion at m/z 396.2245) were also incorporated into the peak finding algorithm (Figure 1a, b). engineered with an expanded peak finding strategy that (i) supports higher charge states, (ii) generates putative catabolic products by cleavage of the amide backbone and disulfide bonds, (iii) considers isotopic distribution of catabolic products, and (iv) interprets MS/MS data using conventional peptide fragmentation patterns. In the current investigation, MetabolitePilot™ was implemented to determine the *in vitro* catabolites of exenatide, obtained using HRAM in SWATH acquisition mode (Sequential Window Acquisition of All Theoretical MS).



Methods

Rat whole blood fortified with exenatide (1 μ g/mL) and incubated at 37°C was sampled at t₀, t₃₀, t_{60} , t_{120} and t_{240} and subsequently precipitated with ethanol:acetonitrile (7:3). Extracts were chromatographed on a Halo Peptide ES-C18 column (2.1 x 150 mm, 5 µm) under gradient conditions at 50°C with an acidified water/acetonitrile mobile phase, ramped from 98% aqueous to 70% organic over 30 minutes. Data was acquired with a SCIEX TripleTOF 5600⁺ operated in SWATH mode using an accumulation time of 100 ms per experiment, where each experiment coincided to fixed 50 Da wide MS/MS windows at 45 eV collision energy for precursor masses 200 - 1250 Da. A research grade version of SCIEX MetabolitePilot[™] Software was used for post-acquisition processing.

Results and Discussion

The post-acquisition processing workflow in research grade MetabolitePilot[™] initially involved defining potential bio-transformations. In addition to the provided default modifications in the Biologics set, custom bio-transformations can be entered, and for exenatide included deamidation (N/Q), oxidative deamination to alcohol (K), demethylation (A/T) and demethylation + oxidation (A/T). The MetabolitePilot[™] processing algorithm always considers hydrolytic cleavages, and for exenatide, generated 702 theoretical catabolites.

The next stage in the MetabolitePilot[™] workflow defined the Peak Finding Strategy, which leverages the TOF-MS data derived from the first experiment in the SWATH acquisition. Within the Processing Parameters dialog, the peptide sequence of exenatide was entered along with an MS/MS reference spectrum from which two diagnostic product ions (y_3 ion at m/z 299.1717 and

New Open Save	Save As	Delete	Method type: Peptid	les	How Do I?
Compound Information S	elect From Library	Sequence			
Compound name: Exenatide		1 H	GEGTFTSDL SKQMEEEAVR LFIEWLKNGG	PSSGAPPPS-[Ami]	
Chemical formula: C184H282N50O60S					
olarity: Positive Negative					
Charge state: From: 2 🔽 To: 5 🔽					
on type: [M+5H] ⁵⁺					
m/z: 837.8127					
	Generic Paramet	ters Compound-Spe	ecific Parameters		
eak Finding Strategy lse this algorithm:	Catabolites Iso	tope Pattern Produ	ct lons and Neutral Losses		
TOF MS					
Predicted metabolites	Potential	Hydrolytic Cleavag	jes		
Generic peak finding	Max. pept	ide bonds to break:	2 🔹 Max. cross-links to break: 0 🔽	Min. AA count: 3	
Apply mass defect filter	Catabolite	s selected: 702			
Apply charge state filter		AA Index	Name	Neutral Formula	Neutral Mass
Mass defect		AA Index	Name	Neutral Formula	Neutral Mass
		1:25-35	WLKNGGPSSGA	C47H72N14O15	Neutral Mass 1072.530
Mass defect Isotope pattern		1:25-35 1:24-33	WLKNGGPSSGA EWLKNGGPSS	C47H72N14O15 C47H71N13O16	Neutral Mass 1072.530 1073.514
Mass defect Isotope pattern TOF MSMS Find characteristic product ions		1:25-35 1:24-33 1:19-26	WLKNGGPSSGA EWLKNGGPSS VRLFIEWL	C47H72N14O15 C47H71N13O16 C54H82N12O11	Neutral Mass 1072.530 1073.514 1074.622
Mass defect Isotope pattern TOF MSMS		1:25-35 1:24-33 1:19-26 1:26-37	WLKNGGPSSGA EWLKNGGPSS VRLFIEWL LKNGGPSSGAPP	C47H72N14O15 C47H71N13O16 C54H82N12O11 C46H76N14O16	Neutral Mass 1072.530 1073.514 1074.622 1080.556
Mass defect Isotope pattern TOF MSMS Find characteristic product ions		1:25-35 1:24-33 1:19-26 1:26-37 1:4-13	WLKNGGPSSGA EWLKNGGPSS VRLFIEWL LKNGGPSSGAPP GTFTSDLSKQ	C47H72N14O15 C47H71N13O16 C54H82N12O11 C46H76N14O16 C46H74N12O18	Neutral Mass 1072.530 1073.514 1074.622 1080.556 1082.524
Mass defect Isotope pattern TOF MSMS Find characteristic product ions All specified ions		1:25-35 1:24-33 1:19-26 1:26-37	WLKNGGPSSGA EWLKNGGPSS VRLFIEWL LKNGGPSSGAPP	C47H72N14O15 C47H71N13O16 C54H82N12O11 C46H76N14O16	Neutral Mass 1072.530 1073.514 1074.622 1080.556
 Mass defect Isotope pattern TOF MSMS Find characteristic product ions All specified ions At least 2 ions 		1:25-35 1:24-33 1:19-26 1:26-37 1:4-13	WLKNGGPSSGA EWLKNGGPSS VRLFIEWL LKNGGPSSGAPP GTFTSDLSKQ	C47H72N14O15 C47H71N13O16 C54H82N12O11 C46H76N14O16 C46H74N12O18	Neutral Mass 1072.530 1073.514 1074.622 1080.556 1082.524
 Mass defect Isotope pattern TOF MSMS Find characteristic product ions All specified ions At least 2 ions Find characteristic neutral losses 		1:25-35 1:24-33 1:19-26 1:26-37 1:4-13 1:3-12	WLKNGGPSSGA EWLKNGGPSS VRLFIEWL LKNGGPSSGAPP GTFTSDLSKQ EGTFTSDLSK	C47H72N14O15 C47H71N13O16 C54H82N12O11 C46H76N14O16 C46H74N12O18 C46H73N11O19	Neutral Mass 1072.530 1073.514 1074.622 1080.556 1082.524 1083.508
 Mass defect Isotope pattern TOF MSMS Find characteristic product ions All specified ions At least 2 ions Find characteristic neutral losses All specified losses 		1:25-35 1:24-33 1:19-26 1:26-37 1:4-13 1:3-12 1:23-32	WLKNGGPSSGA EWLKNGGPSS VRLFIEWL LKNGGPSSGAPP GTFTSDLSKQ EGTFTSDLSK IEWLKNGGPS	C47H72N14O15 C47H71N13O16 C54H82N12O11 C46H76N14O16 C46H74N12O18 C46H73N11O19 C50H77N13O15	Neutral Mass 1072.530 1073.514 1074.622 1080.556 1082.524 1083.508 1099.566

Figure 1a. Processing Parameters workflow in research grade MetabolitePilot[™] Both TOF-MS and TOF-MS/MS data acquired in SWATH mode were incorporated in the peak finding strategy for exenatide catabolites. For a minimum of three amino acid residues, 702 putative catabolites were proposed based on hydrolytic cleavages alone.

Results and Discussion (Continued)


Generic Parameters Compound-Spec	ific Parameters			
Catabolites Isotope Pattern Product	lons and Neutra	I Losses		
Reference MS/MS Spectrum .wiff file Browse C	ompound Library	/		
100 50 0 50 0 50 0 50 299.17	1980 396.2245			83
200	400	600		80
Assig	gn Fragments	m/z	z	F
Filters		299.1717	1	уЗ
Charge	500.0	379.1980	1	y4-1
state: From. 1 10. 5		396.2245	1	y4
Only show product 5	%	837.8156	5	
Mass accuracy 10.00	ppm 🕕		_	
		Add prod	luct id	ons,

Figure 1b. Compound specific parameters indicating the use of y_3 and y_4 product ions incorporated into the peak finding algorithm.

With the Bio-transformation and Processing Parameters established, incubated samples were interrogated against control samples. Proposed catabolites presented in the Results workspace (Figure 2) were considered only if the measured parent mass was within 10 ppm of theoretical and the response was three-fold greater than that observed in control samples. This same mass accuracy was applied to the assignment of product ions measured against theoretical b- and yion masses for proposed catabolite sequences (Figure 2).

lie Luit Setup	Tools He	яр						
Workspace	Oper	1	Save	Save As	. View	v	Show:	Resul
	Det	a mélia l	Meteboli	tes: 7 of 8 F	Deeke			
\odot	Pot			_	Peaks			
Batch		Rep				Nan	ne	
	1		-	Parent [M+5	-			
- * <	2		-	Parent [M+4]	-	KNOODSS		[A] [M 444
Deputto	3							
Results	4							
2020	6							
\geq	7		-					
Correlation				LOITIBLE		IL WENNEG	OF 330Ar	ereo-(Annj (
Workflow								
Compound Library								
Library								
Biotrans-	Inte	rpret	ation Dei	isotope Optio	ns Gene	rate	Assign	Apply
Biotrans- formations				isotope Optio	ns Gene	rate	Assign	Apply
Biotrans-		MS/MS	of 798.9973	isotope Optio		rate	Assign	Apply
Biotrans- formations Processing	+TOF		of 798.9973	isotope Optio	ns Gene	rate	Assign	Apply
Biotrans- formations Processing Parameters	+TOF	MS/MS	of 798.9973	379.1951	396.2235 v v 397.2260	rate		Apply 99.3971
Biotrans- formations Processing Parameters		- MS/MS 1000	of 798.9973		396.2235 v v 397.2260		75	99.3971
Biotrans- formations Processing Parameters	+TOF	- MS/MS 1000	of 798.9973 70.0650 × 71.0699	379.1951 299.1702 √	396.2235 √ √ 397.2260 398.2256	518.2223 √	75 796.198:	99.3971 2 899.:
Biotrans- formations Processing Parameters	+TOF	- MS/MS 1000 500	of 798.9973 70.0650 × 71.0699	379.1951	396.2235 √ √ 397.2260		75	99.3971 2 899. 800 90
Biotrans- formations Processing Parameters	+TOF Intensity, cps	- MS/MS 1000 500 0	of 798.9973 70.0650 × 71.0699 100	379.1951 299.1702 √ 1.1	396.2235 √ √ 397.2260 398.2256	518.2223 √ 600	75 796.198: 700	99.3971 2 899. 800 90 m/z, D
Biotrans- formations Processing Parameters	+TOF sd: , , titeustity Assig	MS/MS 1000 500 0 gned: 9	of 798.9973 70.0650 × 71.0699 100	379.1951 299.1702 √ 11.1	396.2235 √ 397.2260 398.2256 480 500	518.2223 √ 600 ned: 28.69	75 796.198: 700	99.3971 2 899.: 800 90 m/z, D
Biotrans- formations Processing Parameters	+TOF sd: , , titeustity Assig	MS/MS 1000 500 0 gned: 9	of 798.9973 70.0650 × 71.0699 100 8 of 1055 pea its: 98 of 2 Mass	379.1951 299.1702 √ 11.1	396.2235 397.2260 398.2256 480 500 eak Area Assign	518.2223 √ 600 ned: 28.69	796.198: 700 6, Sequer	99.3971 2 899.3 800 90 m/z, D nce Covera
Biotrans- formations Processing Parameters	+TOF sd: , , titeustity Assig	MS/MS 1000 500 0 gned: 9 gmen	of 798.9973 70.0650 × 71.0699 100 3 8 of 1055 pea ts: 98 of 2	379.1951 299.1702 4 200 300 aks, MSMS Pe 239 Propos Sequence	396.2235 397.2260 398.2256 400 500 ak Area Assign ed Formula	518.2223 v 600 ned: 28.69	796.198 700 6, Sequer	99.3971 2 899. 800 90 m/z, D nce Covera Intensity (cps)
Biotrans- formations Processing Parameters	+TOF sdo 'A stisuatu Assig	MS/MS 1000 500 0 gned: 9 gmen Use	of 798.9973 70.0650 × 71.0699 100 8 of 1055 per its: 98 of 2 Mass (m/z) 271.0947	379.1951 299.1702 4 200 300 aks, MSMS Pe 239 Propos Sequence	396.2235 397.2260 398.2256 400 500 ak Area Assign ed Formula	518.2223 √ 600 ned: 28.69 e Charge	796.198. 700 6, Sequer Error (ppm)	99.3971 2 899. 800 90 m/z, D nce Covera Intensity (cps) 0.3
Biotrans- formations Processing Parameters	+TOF sdo 'Atisuutuu Assiig Frag	MS/MS 1000 500 0 gmed: 9 gmen Use	of 798.9973 70.0650 × 71.0699 100 8 of 1055 per its: 98 of 2 Mass (m/z) 271.0947	379.1951 299.1702 √ 200 300 aks, MSMS Pe 239 Propos Sequence EGT PPS-[Ami]	396.2235 397.2260 398.2256 400 500 ak Area Assign ed Formula Ion b3 (- NH3)	518.2223 √ 600 ned: 28.69 e Charge	796.198: 700 6, Sequer Error (ppm) 8.2	99.3971 2 899.3 800 90 m/z, D nce Covera Intensity (cps) 0.3 64.1
Biotrans- formations Processing Parameters	+TOF sdo 'Atsuapu Assig Frag	MS/MS 1000 500 0 gmed: 9 gmen Use Vse	of 798.9973 70.0650 × 71.0699 100 8 of 1055 per its: 98 of 2 Mass (m/z) 271.0947 282.1439 288.1163	379.1951 299.1702 √ 200 300 aks, MSMS Pe 239 Propos Sequence EGT PPS-[Ami]	396.2235 397.2260 398.2256 400 500 eak Area Assign ed Formula lon b3 (- NH3) y3 (- NH3)	518.2223 √ 600 ned: 28.69 e Charge 1 1	796.198 700 6, Sequer Error (ppm) 8.2 -3.5	99.3971 2 899.3 800 90 m/z, D nce Covera (cps) 0.3 64.1 53.3
Biotrans- formations Processing Parameters	+TOF sdo 'Attsuapti Assig Frag	MS/MS 1000 500 0 gned: 9 gmen Use Use V Use	of 798.9973 70.0650 × 71.0699 100 8 of 1055 per its: 98 of 2 Mass (m/z) 271.0947 282.1439 288.1163	379.1951 299.1702 v 200 300 aks, MSMS Pe 200 300 EGT PPS-[Ami] EGT PPS-[Ami]	396.2235 397.2260 398.2256 480 500 eak Area Assign ed Formula lon b3 (- NH3) y3 (- NH3) b3	518.2223 v 600 ned: 28.69 charge 1 1 1	796.198: 700 6, Sequer (ppm) 8.2 -3.5 -9.5	99.3971 2 899.9 800 90 m/z, D nce Covera (cps) 0.3 64.1 53.3
Biotrans- formations Processing Parameters	+TOF sd - ^, isualu	MS/MS 1000 500 0 gmed: 9 gmen Use Use V E	of 798.9973 70.0650 × 71.0699 100 8 of 1055 per its: 98 of 2 Mass (m/z) 271.0947 282.1439 288.1163 299.1702 316.1508	379.1951 299.1702 v 200 300 aks, MSMS Pe 200 300 EGT PPS-[Ami] EGT PPS-[Ami]	396.2235 397.2260 398.2256 400 500 ak Area Assign ed Formula lon b3 (- NH3) y3 (- NH3) b3 y3	518.2223 √ 600 hed: 28.69 charge 1 1 1 1 1	796.198 700 6, Sequer (ppm) 8.2 -3.5 -9.5 -4.0	99.3971 2 899.9 800 90 m/z, D nce Coveray Intensity (cps) 0.3 64.1 53.3 274.3

assignment.






Figure 2. The Results workspace of research grade MetabolitePilot[™] highlights proposed catabolite sequences for exenatide including elemental composition, measured *m/z*, parent mass error and chromatographic retention time. The Interpretation pane plots the catabolite MS/MS spectrum correlating fragment ion mass with sequence information, here for exenatide(3-39). The measured mass error for each fragment ion is also reported. In the Results pane, the XIC from a TOF-MS scan can be plotted against control sample and both the isotope pattern and MS/MS spectrum can be displayed and are incorporated into a scoring

Results and Discussion (Continued)

Results from each time-point were compiled in the Correlation workspace and potential catabolites plotted (Figure 3). In the case of exenatide, only one catabolite demonstrated increased response with incubation time, and coincided to the N-terminal HG clipping biotransformation product exenatide(3-39), whose chromatographic profile and MS/MS spectrum are compared to exenatide in **Figure 4**. Exenatide(4-39), (5-39), and (7-39) catabolites were also detected at incubation times \geq t120, and therefore could not be fully correlated within the time frame of the experiment (Figure 3).



Figure 3. Incubation time profiles for proposed catabolites are generated in the Correlation workspace. The major catabolite for exenatide resulted from N-terminal HG clipping whilst exenatide(4-39), (5-39), and (7-39) were only expressed after t₁₂₀. XICs from the TOF-MS scan of the SWATH acquisition can be plotted at each incubation time point as illustrated for exenatide(3-39).




Figure 4. Comparison of chromatographic retention time and MS/MS SWATH spectra for exenatide and its major catabolite, exenatide(3-39) indicating the highly abundant diagnostic y_3/y_4 ions.


LEARN MORE ABOUT OUR BIOANALYSIS AND RESEARCH SERVICES (>)

Results and Discussion (Continued)

Regardless, each minor putative catabolite generated the diagnostic y_3 - and y_4 - ions of the

exenatide reference spectrum, and each parent mass was measured within 5 ppm of theoretical.

Of particular note, exenatide(3-39) and (4-39) were chromatographically unresolved and their [M+5H]⁺⁵ precursor masses were simultaneously transmitted through the same SWATH window (i.e. m/z 749 – 800), thereby generating a mixed MS/MS spectrum. While a formidable challenge to deconvolute this complex scenario in applications such as PeakView, the advanced algorithm used in MetabolitePilot[™] successfully re-constructed the MS/MS spectrum derived from each of exenatide(3-39) and (4-39), thereby aligning the TOF-MS XICs with confirmatory b- and yfragment ions, as outlined in **Figure 5**.



The research grade version of MetabolitePilot[™] software, when combined with accurate mass measurements from a TripleTOF platform operated in SWATH acquisition mode, represents a formidable platform for protein biotherapeutic catabolism studies. The advanced capabilities of the software algorithm were exemplified in properly assigning co-eluting catabolites of exenatide whose parent masses were simultaneously transmitted through the same SWATH window. A commercial version of MetabolitePilot[™] (v 2.0) is now available which incorporates the peptide sequencing capabilities presented herein.

the SWATH MS/MS experiment for *m/z* 749 – 800 (a) demonstrates a

chromatographic profile suggestive of co-eluting catabolites (b). Since the

SWATH MS/MS spectrum is derived from a 50 Da mass window, it is difficult to

correlate specific fragment ions with precursor mass. However, the advanced

MetabolitePilot[™] algorithm could identify the putative catabolites as exenatide(3-39) and exenatide(4-39) despite their co-elution, and moreover could re-construct the MS/MS spectrum derived from each of the parent masses 798.9973 (c), and 773.1894 (d), respectively. With the MS/MS spectra properly de-convoluted, confirmation of the proposed catabolites was possible. Conclusions

© 2019 Altasciences. All Rights Reserved.